Vicore Pharma’s rights issue registered – conversion of BTA to shares
Not to be released, publication or distribution, directly or indirectly, in or to the United States, Australia, Hong Kong, Singapore, Canada, Japan, New Zealand or South Africa.
Mölndal, November 1, 2018 - Vicore Pharma Holding AB (publ) (”Vicore Pharma” or the ”Company”) has completed a rights issue with the subscription period ending on October 3, 2018. The share issue was oversubscribed with 33 percent and provided the Company with SEK 82,4M before issue costs. The rights issue has now been registered with the Swedish Companies Registration Office (sw. Bolagsverket) and last day of trading in paid subscribed shares (BTA) is on November 6, 2018. BTA will then be converted to shares which are expected to be visible on the respective shareholders’ VP account/custody account on November 12, 2018. The Company’s share is traded on Nasdaq First North.
After conversion of 8,240,002 BTA, the Company will have 32,960,008 outstanding shares.
ISIN code for the share (ticker: VICO): SE0007577895
ISIN code for the BTA (ticker: VICO BTA): SE0011670223
For further information, please contact:
Dr. Carl-Johan Dalsgaard, CEO: +46 709 759 863, firstname.lastname@example.org
About Vicore Pharma Holding AB (publ)
Vicore Pharma AB is focused on the development of drugs for the treatment of interstitial lung diseases. The company’s two major development programs, VP01 (C21) and VP02 (IMiD), act through the AT2 receptor and is an immunomodulatory drug substance class being developed for local treatment, respectively. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. VP02 has in earlier experiments shown an effect in e.g. idiopathic pulmonary fibrosis with another administration form which, however, has limited its continued development. VP02 is being developed for local treatment in order to e.g. overcome such shortcomings. The company is based in AstraZeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com